Belgian Phase 2 biotech company AgomAb Therapeutics (AGMB.US) announced the terms for its U.S. IPO on Thursday, Eastern Time. The company focuses on developing TGFβ inhibitors for Crohn's disease and other fibrotic conditions. It plans to offer 12.5 million shares at a price between $15 and $17 per share to raise $200 million. Based on the midpoint of the proposed price range, AgomAb Therapeutics' fully diluted market capitalization would reach $875 million.

AgomAb Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative disease-modifying therapies for immune and inflammatory diseases. Its initial strategy concentrates on chronic fibrotic indications with high unmet medical needs, functioning by inhibiting a key fibrotic signaling pathway—the Transforming Growth Factor-Beta (TGFβ) pathway. Its lead candidate, ontunisertib (AGMB-129), is a selective, potent, orally administered, gastrointestinal-restricted small molecule inhibitor of ALK5 (TGFβR1), primarily targeting Fibrostenotic Crohn's Disease (FSCD). Another clinical-stage candidate, AGMB-447, is an inhaled ALK5 small molecule inhibitor for treating Idiopathic Pulmonary Fibrosis (IPF).

Furthermore, the company has a preclinical candidate—an HGF-mimetic monoclonal antibody targeting liver cirrhosis. AgomAb has completed the studies required for an Investigational New Drug (IND) application and is currently evaluating subsequent development and strategic partnership options. Founded in 2017, AgomAb Therapeutics plans to list on the Nasdaq under the ticker symbol "AGMB". The joint book-running managers for the offering are J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen. The company expects to price the IPO this February.